Sign In
Buy SGEN
$228.74
+0 (+0%)
At Close: Mar 12, 2024
Seagen (SGEN) Q3 Loss Widens, Revenues Beat, 2021 Guidance Up
02:30pm, Friday, 29'th Oct 2021
Seagen's (SGEN) earnings miss estimates in the third quarter of 2021 while revenues beat the same. The company increases its financial guidance for 2021.
Seagen Inc. (SGEN) CEO Clay Siegall on Q3 2021 Results - Earnings Call Transcript
09:29pm, Thursday, 28'th Oct 2021
Seagen Inc. (SGEN) CEO Clay Siegall on Q3 2021 Results - Earnings Call Transcript
Seattle Genetics (SGEN) Reports Q3 Loss, Tops Revenue Estimates
07:06pm, Thursday, 28'th Oct 2021
Seattle Genetics (SGEN) delivered earnings and revenue surprises of -187.50% and 9.68%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Seagen (SGEN) Might Surprise This Earnings Season
10:39am, Wednesday, 27'th Oct 2021
Seagen (SGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Seattle Genetics's Earnings Outlook
10:26am, Wednesday, 27'th Oct 2021
Seattle Genetics (NASDAQ:SGEN) is set to give its latest quarterly earnings report on Thursday, 2021-10-28. Here's what investors need to know before the announcement.
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
02:15pm, Friday, 01'st Oct 2021
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new molecular entities, or NM
Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
03:00am, Monday, 27'th Sep 2021
TOKYO and BOTHELL, Wash., Sept. 27, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)
05:24am, Wednesday, 22'nd Sep 2021
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Seagen, Inc. (SGEN) FDA approval of TIVDAK Conference Call (Transcript)
03:49pm, Tuesday, 21'st Sep 2021
Seagen, Inc. (SGEN) FDA approval of TIVDAK Conference Call (Transcript)
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer
10:49am, Tuesday, 21'st Sep 2021
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
FDA Gives Accelerated Approval to Seagen - Genmab's ADC In Cervical Cancer
08:15am, Tuesday, 21'st Sep 2021
The FDA handed an accelerated approval to Seagen Inc (NASDAQ: SGEN) and Genmab A/S' (NASDAQ: GMAB) Tivdak (tisotumab vedotin-tftv, or TV). The nod comes for second-line patients with recurrent o
Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval
05:05pm, Monday, 20'th Sep 2021
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) will host a conference call and webcast on Tuesday, September 21, 2021 to discuss the U.S. Food and Drug Administration approval of TIVDAK�
Seagen, Genmab Present Tisotumab Vedotin Combo Data In Cervical Cancer
06:47am, Monday, 20'th Sep 2021
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) have interim data from two Phase 1b/2 innovaTV 205 trial cohorts. The trial is evaluating its antibody-drug conjugate tisotumab vedotin (TV
Seagen Stock Is A Buy For Its Pipeline Value
01:42pm, Wednesday, 15'th Sep 2021
Current revenue and cash support the R&D effort.
